American biotech company Sanofi Genzyme voluntarily recalled a lot of over 12,000 Synvisc-One (hylan G-F 20) syringes on December 11, 2017.
Synvisc-One is a drug to relieve knee pain in patients with osteoarthritis. The gel inside the syringe is reportedly contaminated with certain microbes that may increase patients’ risk of infection.
Sanofi revealed that the microbes are resistant to many antibiotics and are, therefore, difficult to treat.
WHAT IS OSTEOARTHRITIS?
Osteoarthritis is a chronic condition in which joints deteriorate over time. This “wear-and-tear” arthritis often develops as a person ages, but it can also be hereditary or due to other illnesses or repetitive injuries.
Various treatments alleviate pain and return mobility, but there’s no cure.
WHY SYNVISC-ONE WORKS
Synvisc-One is prescribed to patients who haven’t responded well to other medications.
The medication contains hyaluronic acid, a substance that absorbs shock and lubricates joints. While naturally present in healthy joints, the substance seems to break down in osteoarthritis patients.
Patients find that injecting the medication into their knees eases the pain and inflammation they feel from their arthritis.
For a free legal consultation, call (800) 794-0444
SANOFI IN THE NEWS
This isn’t the first time the biotech giant is in the news.
In December 2015, one of the company’s chemotherapy drugs, Taxotere, was given the FDA’s most severe warning after it was found to cause permanent hair loss.
Although hair loss is a common side effect of many chemotherapy drugs, Taxotere may prevent patients’ hair from ever growing back.
HOW WE CAN HELP
We are now accepting Synvisc-One Injury cases. If you’ve been using an osteoarthritis medication, but aren’t sure if it was the contaminated lot of Synvisc-One, our lawyers can do the research for you and help you explore your legal options.
Our dangerous drug attorneys have recovered millions of dollars for drug injury victims. Contact us today for your free consultation.